

Title (en)  
USE OF SUBSTITUTED 11-PHENYL-DIBENZAZEPINE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SICKLE CELL DISEASE, INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION, DIARRHEA AND SCOUR

Title (de)  
VERWENDUNG VON 11-PHENYL SUBSTITUIRTEN DIBENZAZEPIN-DERIVATE ZUR BEHANDLUNG ODER VORBEUGUNG VON SICHELZELLANÄMIE, ENTZÜNTLICHEN ERKRANKUNGEN, DIE DURCH EINE ABNORMALE ZELLPROLIFERATION GEKENZEICHNET SIND, DIARRHÖE UND DIARRHÖE BEI TIEREN

Title (fr)  
UTILISATION DE COMPOSES 11-PHENYL-DIBENZAZEPINE SUBSTITUES DANS LE TRAITEMENT OU LA PREVENTION DE LA DREPANOCYTOSE, DES MALADIES INFLAMMATOIRES CARACTERISEES PAR UNE PROLIFERATION CELLULAIRE ANORMALE ET PAR LA DIARRHEE CHEZ L'HOMME ET L'ANIMAL

Publication  
**EP 1032394 A1 20000906 (EN)**

Application  
**EP 98960380 A 19981120**

Priority

- US 9824967 W 19981120
- US 97559497 A 19971120
- US 15933398 A 19980923
- US 15933798 A 19980923

Abstract (en)  
[origin: WO9926628A1] The present invention provides substituted 11-phenyl-dibenzazepine compounds, as well as analogues thereof, which are specific, potent and safe inhibitors of the Ca<sup>2+</sup>-activated potassium channel (Gardos channel) of erythrocytes, of mammalian cell proliferation and/or of secretagogue-stimulated transepithelial electrogenic chloride secretion in intestinal cells. The compounds can be used to reduce sickle erythrocyte dehydration and/or delay the occurrence of erythrocyte sickling or deformation in situ as a therapeutic approach towards the treatment or prevention of sickle cell disease. The compounds can also be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation. Furthermore, the compounds can also be used to inhibit chloride secretion in intestinal cells as a therapeutic approach towards the treatment of diarrhea and scours.

IPC 1-7  
**A61K 31/55**; **C07D 223/20**

IPC 8 full level  
**A61K 31/55** (2006.01); **A61P 1/00** (2006.01); **A61P 9/10** (2006.01); **A61P 11/06** (2006.01); **A61P 13/12** (2006.01); **A61P 17/00** (2006.01); **A61P 29/00** (2006.01); **A61P 37/02** (2006.01); **A61P 43/00** (2006.01); **C07D 223/20** (2006.01)

CPC (source: EP)  
**A61K 31/55** (2013.01); **A61P 1/00** (2017.12); **A61P 9/10** (2017.12); **A61P 11/06** (2017.12); **A61P 13/12** (2017.12); **A61P 17/00** (2017.12); **A61P 29/00** (2017.12); **A61P 37/02** (2017.12); **A61P 43/00** (2017.12); **C07D 223/20** (2013.01)

Citation (search report)  
See references of WO 9926628A1

Designated contracting state (EPC)  
AT BE CH DE DK ES FR GB IE IT LI LU NL PT SE

DOCDB simple family (publication)  
**WO 9926628 A1 19990603**; AU 1598799 A 19990615; CA 2310773 A1 19990603; EP 1032394 A1 20000906; IL 136209 A0 20010520; JP 2001523720 A 20011127

DOCDB simple family (application)  
**US 9824967 W 19981120**; AU 1598799 A 19981120; CA 2310773 A 19981120; EP 98960380 A 19981120; IL 13620998 A 19981120; JP 2000521830 A 19981120